Radiolabeled Human Serum Albumin Nanoparticles Co-Loaded with Methotrexate and Decorated with Trastuzumab for Breast Cancer Diagnosis

Basit Öğe Kaydı
dc.authoridLopes, André Moreni/0000-0002-3570-2470
dc.authoridAlencar, Luciana Magalhães Rebelo/0000-0001-8210-2016
dc.authoridEKINCI, MELIHA/0000-0003-1319-3756
dc.authoridsantos-oliveira, ralph/0000-0002-0905-481X
dc.authorscopusid56661951100
dc.authorscopusid57316016100
dc.authorscopusid23486135800
dc.authorscopusid55945269600
dc.authorscopusid55748265800
dc.authorwosidLopes, André Moreni/E-9058-2013
dc.authorwosidAlencar, Luciana Magalhães Rebelo/O-6736-2018
dc.authorwosidsantos-oliveira, ralph/J-8363-2013
dc.authorwosidEKINCI, MELIHA/V-9829-2017
dc.contributor.authorEkinci, Meliha
dc.contributor.authorAlencar, Luciana Magalhaes Rebelo
dc.contributor.authorLopes, Andre Moreni
dc.contributor.authorSantos-Oliveira, Ralph
dc.contributor.authorİlem-Özdemir, Derya
dc.date.accessioned2024-08-25T18:52:07Z
dc.date.available2024-08-25T18:52:07Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBreast cancer is a leading cause of cancer-related mortality among women worldwide, with millions of new cases diagnosed yearly. Addressing the burden of breast cancer mortality requires a comprehensive approach involving early detection, accurate diagnosis, effective treatment, and equitable access to healthcare services. In this direction, nano-radiopharmaceuticals have shown potential for enhancing breast cancer diagnosis by combining the benefits of nanoparticles and radiopharmaceutical agents. These nanoscale formulations can provide improved imaging capabilities, increased targeting specificity, and enhanced sensitivity for detecting breast cancer lesions. In this study, we developed and evaluated a novel nano-radio radiopharmaceutical, technetium-99m ([Tc-99m]Tc)-labeled trastuzumab (TRZ)-decorated methotrexate (MTX)-loaded human serum albumin (HSA) nanoparticles ([Tc-99m]-TRZ-MTX-HSA), for the diagnosis of breast cancer. In this context, HSA and MTX-HSA nanoparticles were prepared. Conjugation of MTX-HSA nanoparticles with TRZ was performed using adsorption and covalent bonding methods. The prepared formulations were evaluated for particle size, PDI value, zeta (zeta) potential, scanning electron microscopy analysis, encapsulation efficiency, and loading capacity and cytotoxicity on MCF-7, 4T1, and MCF-10A cells. Finally, the nanoparticles were radiolabeled with [Tc-99m]Tc using the direct radiolabeling method, and cellular uptake was performed with the nano-radiopharmaceutical. The results showed the formation of spherical nanoparticles, with a particle size of 224.1 +/- 2.46 nm, a PDI value of 0.09 +/- 0.07, and a zeta potential value of -16.4 +/- 0.53 mV. The encapsulation efficiency of MTX was found to be 32.46 +/- 1.12%, and the amount of TRZ was 80.26 +/- 1.96%. The labeling with [Tc-99m]Tc showed a high labeling efficiency (>99%). The cytotoxicity studies showed no effect, and the cellular uptake studies showed 97.54 +/- 2.16% uptake in MCF-7 cells at the 120th min and were found to have a 3-fold higher uptake in cancer cells than in healthy cells. In conclusion, [Tc-99m]Tc-TRZ-MTX-HSA nanoparticles are promising for diagnosing breast cancer and evaluating the response to treatment in breast cancer patients.en_US
dc.description.sponsorshipEge University Scientific Research Projects Coordination Unit [22933]; Ege University Scientific Research Projects Coordination Unit [22933]en_US
dc.description.sponsorshipThis study was financially supported by the Ege University Scientific Research Projects Coordination Unit (Project number-22933)en_US
dc.identifier.doi10.3390/jfb14090477
dc.identifier.issn2079-4983
dc.identifier.issue9en_US
dc.identifier.pmid37754891en_US
dc.identifier.scopus2-s2.0-85172226567en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.3390/jfb14090477
dc.identifier.urihttps://hdl.handle.net/11454/102832
dc.identifier.volume14en_US
dc.identifier.wosWOS:001076367000001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofJournal of Functional Biomaterialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectmonoclonal antibodyen_US
dc.subjectfolate receptoren_US
dc.subjectnanotechnologyen_US
dc.subjectdiagnosisen_US
dc.subjectcanceren_US
dc.subjectIn-Vitro Evaluationen_US
dc.subjectDrug-Delivery-Systemen_US
dc.subjectConjugated Nanoparticlesen_US
dc.subjectPharmacoscintigraphic Evaluationen_US
dc.subjectOptimizationen_US
dc.subjectLiposomesen_US
dc.subjectCellsen_US
dc.subjectDoxorubicinen_US
dc.subjectExpressionen_US
dc.subjectEfficacyen_US
dc.titleRadiolabeled Human Serum Albumin Nanoparticles Co-Loaded with Methotrexate and Decorated with Trastuzumab for Breast Cancer Diagnosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu